New insights into the role of the immune microenvironment in breast carcinoma

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  De La Cruz Merino, Luis ^a   Barco Sánchez, Antonio ^a   Henao Carrasco, Fernando ^a   Nogales Fernández, Esteban ^a   Vallejo Benítez, Ana ^a   Brugal Molina, Javier ^a   Martínez Peinado, Antonio ^a   Grueso López, Ana ^a   Ruiz Borrego, Manuel ^b   Codes Manuel De Villena, Manuel ^a   Sánchez Margalet, Víctor ^a   Nieto García, Adoración ^c   Alba Conejo, Emilio ^d   Casares Lagar, Noelia ^e   Ibáñez Martínez, José ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; CYTOKINE; DENILEUKIN DIFTITOX; IPILIMUMAB; TRASTUZUMAB;

ALGORITHM; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; HUMAN; IMMUNOLOGICAL TOLERANCE; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; BONE MARROW CELL; BREAST TUMOR; CARCINOMA; FEMALE; IMMUNOLOGICAL SYNAPSE; IMMUNOLOGY; MACROPHAGE; PATHOLOGY; PROGNOSIS; REVIEW; TUMOR MICROENVIRONMENT; BREAST NEOPLASMS;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGICAL SYNAPSES; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MYELOID CELLS; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 84879294912     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/785317     Document Type: Article

References (93)

1. Demaria S., Volm M. D., Shapiro R. L., Yee H. T., Oratz R., Formenti S. C., Muggia F., Symmans W. F., Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clinical Cancer Research 2001 7 10 3025 3030 2-s2.0-0034796870
2. Denkert C., Loibl S., Noske A., Roller M., Müller B. M., Komor M., Budczies J., Darb-Esfahani S., Kronenwett R., Hanusch C., Von Törne C., Weichert W., Engels K., Solbach C., Schrader I., Dietel M., Von Minckwitz G., Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology 2010 28 1 105 113 2-s2.0-73949092850 10.1200/JCO.2009.23.7370
3. Schmidt M., Bohm D., von Torne C., The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Research 2008 68 5405 5413
4. + regulatory T cells. Clinical Cancer Research 2008 14 8 2413 2420 2-s2.0-42249115188 10.1158/1078-0432.CCR-07-4491
5. + regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clinical Cancer Research 2007 13 9 2714 2721 2-s2.0-34249074242 10.1158/1078-0432.CCR-06-2347
6. + lymphocytes predict clinical outcome in breast cancer. Journal of Clinical Oncology 2011 29 15 1949 1955 2-s2.0-79956329617 10.1200/JCO.2010.30.5037
7. Haanen J. B. A. G., Baars A., Gomez R., Weder P., Smits M., De Gruijl T. D., Von Blomberg B. M. E., Bloemena E., Scheper R. J., Van Ham S. M., Pinedo H. M., Van Den Eertwegh A. J. M., Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunology, Immunotherapy 2006 55 4 451 458 2-s2.0-30444443011 10.1007/s00262-005-0018-5
8. Pages F., Berger A., Camus M., Effector memory T cells, early metastasis, and survival in colorectal cancer. The New England Journal of Medicine 2005 353 2654 2666
9. Zhang L., Conejo-Garcia J. R., Katsaros D., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England Journal of Medicine 2003 348 203 213
10. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoué F., Bruneval P., Cugnenc P. H., Trajanoski Z., Fridman W. H., Pagès F., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 313 5795 1960 1964 2-s2.0-33749319703 10.1126/science.1129139
11. Nishikawa H., Sakaguchi S., Regulatory T cells in tumor immunity. International Journal of Cancer 2010 127 4 759 767 2-s2.0-77954721060 10.1002/ijc.25429
12. + regulatory t cells from human peripheral blood. Journal of Immunology 2001 166 12 7282 7289 2-s2.0-0035876913
13. + regulatory T cells. Nature Immunology 2003 4 330 336
14. Hori S., Nomura T., Sakaguchi S., Control of regulatory T cell development by the transcription factor Foxp3. Science 2003 299 5609 1057 1061 2-s2.0-0347785480 10.1126/science.1079490
15. Gavin M. A., Rasmussen J. P., Fontenot J. D., Vasta V., Manganiello V. C., Beavo J. A., Rudensky A. Y., Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007 445 7129 771 775 2-s2.0-33847153417 10.1038/nature05543
16. Zheng Y., Josefowicz S. Z., Kas A., Chu T. T., Gavin M. A., Rudensky A. Y., Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007 445 7130 936 940 2-s2.0-33847220736 10.1038/nature05563
17. Vignali D. A. A., Collison L. W., Workman C. J., How regulatory T cells work. Nature Reviews Immunology 2008 8 7 523 532 2-s2.0-46249101518 10.1038/nri2343
18. Collison L. W., Pillai M. R., Chaturvedi V., Vignali D. A. A., Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. Journal of Immunology 2009 182 10 6121 6128 2-s2.0-70049118519 10.4049/jimmunol.0803646
19. De la Cruz-Merino L., Henao-Carrasco F., García-Manrique T., Role of transforming growth factor beta in cancer microenvironment. Clinical and Translational Oncology 2009 11 11 715 720
20. Bates G. J., Fox S. B., Han C., Leek R. D., Garcia J. F., Harris A. L., Banham A. H., Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of Clinical Oncology 2006 24 34 5373 5380 2-s2.0-34247261531 10.1200/JCO.2006.05. 9584
21. Balsari A., Merlo A., Casalini P., Carcangiu M. L., Malventano C., Triulzi T., Menard S., Tagliabue E., FOXP3 expression and overall survival in breast cancer. Journal of Clinical Oncology 2009 27 11 1746 1752 2-s2.0-64649088372 10.1200/JCO.2008.17.9036
22. Ladoire S., Mignot G., Dalban C., FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Annals of Oncology 2012 23 2552 2256
23. Ladoire S., Arnould L., Mignot G., Coudert B., Rébé C., Chalmin F., Vincent J., Bruchard M., Chauffert B., Martin F., Fumoleau P., Ghiringhelli F., Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment 2011 125 1 65 72 2-s2.0-78651098988 10.1007/s10549-010-0831-1
24. Wolf A. M., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B., Increase of regulatory T cells in the peripheral blood of cancer patients. Clinical Cancer Research 2003 9 2 606 612 2-s2.0-0037312480
25. Liyanage U. K., Moore T. T., Joo H. G., Tanaka Y., Herrmann V., Doherty G., Drebin J. A., Strasberg S. M., Eberlein T. J., Goedegebuure P. S., Linehan D. C., Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Journal of Immunology 2002 169 5 2756 2761 2-s2.0-0036721629
26. Abbas A. K., Lichtman A. H., Pillai S., Abbas A. K., Lichtman A. H., Pillai S., Immunity to tumors. Cellular and Molecular Immunology 2007 6th Philadelphia, Pa, USA Saunders Elsevier 397 417
27. Sharpe A. H., Abbas A. K., T-cell costimulation-biology, therapeutic potential, and challenges. The New England Journal of Medicine 2006 355 10 973 975 2-s2.0-33748428203 10.1056/NEJMp068087
28. Fonsatti E., Maio M., Altomonte M., Hersey P., Biology and clinical applications of CD40 in cancer treatment. Seminars in Oncology 2010 37 5 517 523 2-s2.0-78449262545 10.1053/j.seminoncol.2010.09.002
29. Grewal I. S., Flavell R. A., CD40 and CD154 in cell-mediated immunity. Annual Review of Immunology 1998 16 111 135 2-s2.0-0031944607 10.1146/annurev.immunol.16.1.111
30. Dunn G. P., Old L. J., Schreiber R. D., The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004 21 2 137 148 2-s2.0-4143141823 10.1016/j.immuni.2004.07.017
31. De La Cruz-Merino L., Grande-Pulido E., Albero-Tamarit A., De Villena M. E. C. M., Cancer and immune response: old and new evidence for future challenges. Oncologist 2008 13 12 1246 1254 2-s2.0-58749109167 10.1634/theoncologist.2008-0166
32. Mao H., Zhang L., Yang Y., Zuo W., Bi Y., Gao W., Deng B., Sun J., Shao Q., Qu X., New insights of CTLA-4 into its biological function in breast cancer. Current Cancer Drug Targets 2010 10 7 728 736 2-s2.0-78649237729
33. Azuma T., Yao S., Zhu G., Flies A. S., B7-H1 is a ubiquitous anti-apoptotic receptor on cancer cells. Blood 2008 111 3635 3643
34. Parekh V. V., Lalani S., Kim S., Halder R., Azuma M., Yagita H., Kumar V., Wu L., Van Kaer L., PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. Journal of Immunology 2009 182 5 2816 2826 2-s2.0-64849116017 10.4049/jimmunol.0803648
35. Weber J., Immune checkpoint proteins: a new therapeutic paradigm for cancerpreclinical background: CTLA-4 and PD-1 blockade. Seminars in Oncology 2010 37 5 430 439 2-s2.0-78449243489 10.1053/j.seminoncol.2010.09.005
36. Ghebeh H., Mohammed S., Al-Omair A., Qattan A., Lehe C., Al-Qudaihi G., Elkum N., Alshabanah M., Amer S. B., Tulbah A., Ajarim D., Al-Tweigeri T., Dermime S. D., The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006 8 3 190 198 2-s2.0-33646367200 10.1593/neo.05733
37. Jensen S. M., Maston L. D., Gough M. J., Ruby C. E., Redmond W. L., Crittenden M., Li Y., Puri S., Poehlein C. H., Morris N., Kovacsovics-Bankowski M., Moudgil T., Twitty C., Walker E. B., Hu H. M., Urba W. J., Weinberg A. D., Curti B., Fox B. A., Signaling through OX40 enhances antitumor immunity. Seminars in Oncology 2010 37 5 524 532 2-s2.0-78449237498 10.1053/j.seminoncol. 2010.09.013
38. Redmond W. L., Ruby C. E., Weinberg A. D., The role of OX40-mediated co-stimulation in T-cell activation and survival. Critical Reviews in Immunology 2009 29 187 201
39. Ruby C. E., Montler R., Zheng R., Shu S., Weinberg A. D., IL-12 is required for anti-OX40-mediated CD4 T cell survival. Journal of Immunology 2008 180 4 2140 2148 2-s2.0-42149095015
40. Grivennikov S. I., Greten F. R., Karin M., Immunity, inflammation, and cancer. Cell 2010 140 6 883 899 2-s2.0-77950346282 10.1016/j.cell.2010.01.025
41. Ostrand-Rosenberg S., Sinha P., Myeloid-derived suppressor cells: linking inflammation and cancer. Journal of Immunology 2009 182 8 4499 4506 2-s2.0-65249138393 10.4049/jimmunol.0802740
42. Movahedi K., Laoui D., Gysemans C., Baeten M., Stangé G., Van Bossche J. D., Mack M., Pipeleers D., In't Veld P., De Baetselier P., Van Ginderachter J. A., Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Research 2010 70 14 5728 5739 2-s2.0-77955038532 10.1158/0008-5472.CAN-09-4672
43. Zamarron B. F., Chen W., Dual roles of immune cells and their factors in cancer development and progression. International Journal of Biological Sciences 2011 7 5 651 658 2-s2.0-79960122931
44. Biswas S. K., Mantovani A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology 2010 11 10 889 896 2-s2.0-77956976681 10.1038/ni.1937
45. Khramtsova G., Liao C., Khramtsov A., The M2/alternatively activated macrophage phenotype correlates with aggressive histopathologic features and poor clinical outcome in early stage breast cancer. Cancer Research 2009 69 24 Supplement, Abstract 107
46. Nagaraj S., Gabrilovich D. I., Myeloid-derived suppressor cells in human cancer. Cancer Journal 2010 16 4 348 353 2-s2.0-77957991455 10.1097/PPO. 0b013e3181eb3358
47. Gabrilovich D. I., Nagaraj S., Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 2009 9 3 162 174 2-s2.0-61349100687 10.1038/nri2506
48. Cole S., Montero A., Garret-Mayer E., Elevated circulating myeloid derived suppressor cells (MDSC) are associated with inferior overall survival and correlate with circulating tumor cells (CTC) in patients with metastatic breast cancer. Cancer Research 2009 69 24 Supplement, Abstract 4135
49. + regulatory T cells by TGF- β induction of transcription factor Foxp3. Journal of Experimental Medicine 2003 198 12 1875 1886 2-s2.0-0348223787 10.1084/jem.20030152
50. Lin W. W., Karin M., A cytokine-mediated link between innate immunity, inflammation, and cancer. Journal of Clinical Investigation 2007 117 5 1175 1183 2-s2.0-34248141100 10.1172/JCI31537
51. Waller E. K., The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist 2007 12 2 22 26 2-s2.0-38449111918 10.1634/theoncologist.12-S2-22
52. Spitler L. E., Grossbard M. L., Ernstoff M. S., Silver G., Jacobs M., Hayes F. A., Soong S. J., Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. Journal of Clinical Oncology 2000 18 8 1614 1621 2-s2.0-0033998594
53. Correale P., Cusi M. G., Tsang K. Y., Del Vecchio M. T., Marsili S., La Placa M., Intrivici C., Aquino A., Micheli L., Nencini C., Ferrari F., Giorgi G., Bonmassar E., Francini G., Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. Journal of Clinical Oncology 2005 23 35 8950 8958 2-s2.0-33644789357 10.1200/JCO.2005.12.147
54. Honkoop A. H., Luykx-De Barker S. A., Hoekman K., Meyer S., Meyer O. W. M., Van Groeningen C. J., Van Diest P. J., Boven E., Van Der Wall E., Giaccone G., Wagstaff J., Pinedo H. M., Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist 1999 4 2 106 111 2-s2.0-0032946705
55. Pinedo H. M., De Gruijl T. D., Van Der Wall E., Buter J., Biological concepts of prolonged neoadjuvant treatment plus GM-CSF in locally advanced tumors. Oncologist 2000 5 6 497 500 2-s2.0-0033672784
56. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005 105 7 2862 2868 2-s2.0-15944410592 10.1182/blood-2004-06-2410
57. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunology, Immunotherapy 2007 56 5 641 648 2-s2.0-33847368549 10.1007/s00262-006-0225-8
58. Attia P., Maker A. V., Haworth L. R., Rogers-Freezer L., Rosenberg S. A., Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. Journal of Immunotherapy 2005 28 6 582 592 2-s2.0-27444435581
59. Litzinger M. T., Fernando R., Curiel T. J., Grosenbach D. W., Schlom J., Palena C., IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007 110 9 3192 3201 2-s2.0-36148939150 10.1182/blood-2007-06-094615
60. Curiel T. J., Regulatory T cells and treatment of cancer. Current Opinion in Immunology 2008 20 2 241 246 2-s2.0-44749092510 10.1016/j.coi.2008.04.008
61. + regulatory T cell function. Science 2008 322 5899 271 275 2-s2.0-53749094183 10.1126/science.1160062
62. Peggs K. S., Quezada S. A., Chambers C. A., Korman A. J., Allison J. P., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. Journal of Experimental Medicine 2009 206 8 1717 1725 2-s2.0-68149155982 10.1084/jem.20082492
63. Khan S., Burt D. J., Ralph C., Thistlethwaite F. C., Hawkins R. E., Elkord E., Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clinical Immunology 2011 138 1 85 96 2-s2.0-78651364767 10.1016/j.clim.2010.09. 011
64. Robert C., Ghiringhelli F., What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 2009 14 8 848 861 2-s2.0-70249083099 10.1634/theoncologist.2009-0028
65. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010 363 8 711 723 2-s2.0-77954801079 10.1056/NEJMoa1003466
66. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J. F., Testori A., Grob J. J., Davidson N., Richards J., Maio M., Hauschild A., Miller W. H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T. T., Humphrey R., Hoos A., Wolchok J. D., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine 2011 364 26 2517 2526 2-s2.0-79959772576 10.1056/NEJMoa1104621
67. Calabr L., Danielli R., Sigalotti L., Maio M., Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Seminars in Oncology 2010 37 5 460 467 2-s2.0-78449251207 10.1053/j.seminoncol.2010.09.006
68. Vonderheide R., LoRusso P. M., Khalil M., Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of ICOS expression on patient T cells. Clinical Cancer Research 2010 16 3485 3494
69. Tarhini A. A., Iqbal F., CTLA-4 blockade: therapeutic potential in cancer treatments. OncoTargets and Therapy 2010 3 15 25 2-s2.0-77953378992
70. Curran M. A., Montalvo W., Yagita H., Allison J. P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America 2010 107 9 4275 4280 2-s2.0-77749279776 10.1073/pnas.0915174107
71. Brahmer J. R., Drake C. G., Wollner I., Powderly J. D., Picus J., Sharfman W. H., Stankevich E., Pons A., Salay T. M., McMiller T. L., Gilson M. M., Wang C., Selby M., Taube J. M., Anders R., Chen L., Korman A. J., Pardoll D. M., Lowy I., Topalian S. L., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology 2010 28 19 3167 3175 2-s2.0-77954899030 10.1200/JCO.2009.26.7609
72. + T-cell tolerance to T-cell priming through in vivo ligation of cd40. Nature Medicine 1999 5 7 780 787 2-s2.0-0032984347 10.1038/10503
73. Diehl L., Den Boer A. T., Schoenberger S. P., Van Der Voort E. I. H., Schumacher T. N. M., Melief C. J. M., Offringa R., Toes R. E. M., CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Medicine 1999 5 7 774 779 2-s2.0-0032984496 10.1038/10495
74. Beatty G. L., Chiorean E. G., Fishman M. P., Saboury B., Teitelbaum U. R., Sun W., Huhn R. D., Song W., Li D., Sharp L. L., Torigian D. A., O'Dwyer P. J., Vonderheide R. H., CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011 331 6024 1612 1616 2-s2.0-79953154967 10.1126/science.1198443
75. Takeda K., Kojima Y., Uno T., Hayakawa Y., Teng M. W. L., Yoshizawa H., Yagita H., Gejyo F., Okumura K., Smyth M. J., Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. Journal of Immunology 2010 184 10 5493 5501 2-s2.0-77954704783 10.4049/jimmunol.0903033
76. + T cell tolerance to an endogenous tumor antigen. Journal of Immunology 2006 176 2 974 983 2-s2.0-30744445700
77. Hirschhorn-Cymerman D., Rizzuto G. A., Merghoub T., Cohen A. D., Avogadri F., Lesokhin A. M., Weinberg A. D., Wolchok J. D., Houghton A. N., OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. Journal of Experimental Medicine 2009 206 5 1103 1116 2-s2.0-66049113612 10.1084/jem.20082205
78. Gough M. J., Crittenden M. R., Sarff M., Pang P., Seung S. K., Vetto J. T., Hu H. M., Redmond W. L., Holland J., Weinberg A. D., Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. Journal of Immunotherapy 2010 33 8 798 809 2-s2.0-77958047687 10.1097/CJI.0b013e3181ee7095
79. Wolchok J. D., Hoos A., O'Day S., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical Cancer Research 2009 15 7412 7420
80. Zitvogel L., Apetoh L., Ghiringhelli F., André F., Tesniere A., Kroemer G., The anticancer immune response: indispensable for therapeutic success? Journal of Clinical Investigation 2008 118 6 1991 2001 2-s2.0-45749134564 10.1172/JCI35180
81. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine 2007 13 1050 1059
82. Obeid M., Tesniere A., Panaretakis T., Tufi R., Joza N., Ecto-calreticulin in immunogenic chemotherapy. Immunological Reviews 2007 220 22 34
83. Nowak A. K., Robinson B. W. S., Lake R. A., Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Research 2003 63 15 4490 4496 2-s2.0-0042591416
84. Casares N., Pequignot M. O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., Schmitt E., Hamai A., Hervas-Stubbs S., Obeid M., Coutant F., Métivier D., Pichard E., Aucouturier P., Pierron G., Garrido C., Zitvogel L., Kroemer G., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. Journal of Experimental Medicine 2005 202 12 1691 1701 2-s2.0-29144530630 10.1084/jem.20050915
85. Haynes N. M., van der Most R. G., Lake R. A., Smyth M. J., Immunogenic anti-cancer chemotherapy as an emerging concept. Current Opinion in Immunology 2008 20 5 545 557 2-s2.0-50549088118 10.1016/j.coi.2008.05.008
86. Tesniere A., Apetoh L., Ghiringhelli F., Joza N., Panaretakis T., Kepp O., Schlemmer F., Zitvogel L., Kroemer G., Immunogenic cancer cell death: a key-lock paradigm. Current Opinion in Immunology 2008 20 5 504 511 2-s2.0-50549102898 10.1016/j.coi.2008.05.007
87. Lake R. A., Robinson B. W. S., Immunotherapy and chemotherapy-a practical partnership. Nature Reviews Cancer 2005 5 397 405
88. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research 2005 11 18 6713 6721 2-s2.0-25144466458 10.1158/1078-0432.CCR-05-0883
89. Lake R. A., van der Most R. G., A better way for a cancer cell to die. The New England Journal of Medicine 2006 354 2503 2504
90. Rüttinger D., Winter H., Van Den Engel N. K., Hatz R., Jauch K. W., Fox B. A., Weber J. S., Immunotherapy of cancer: key findings and commentary on the third tegernsee conference. Oncologist 2010 15 1 112 118 2-s2.0-75649120787 10.1634/theoncologist.2009-0213
91. Flowers C. R., Sinha R., Vose J. M., Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer Journal for Clinicians 2010 60 6 393 408 2-s2.0-78649391451 10.3322/caac.20087
92. Guarneri V., Barbieri E., Dieci M. V., Piacentini F., Conte P., Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treatment Reviews 2010 36 3 S62 S66 2-s2.0-78649732997 10.1016/S0305-7372(10) 70022-0
93. Mittendorf E. A., Storrer C. E., Shriver C. D., Ponniah S., Peoples G. E., Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Annals of Surgical Oncology 2006 13 8 1085 1098 2-s2.0-33748347895 10.1245/ASO.2006.03.069